{
    "clinical_study": {
        "@rank": "1", 
        "arm_group": {
            "arm_group_label": "botulinum toxin Type A", 
            "arm_group_type": "Experimental", 
            "description": "Botulinum toxin Type A injected across specific head and neck muscles on Day 0."
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate the safety and efficacy of BOTOX\u00ae treatment in Korean adults with\n      chronic migraine."
        }, 
        "brief_title": "A Safety and Efficacy Study of BOTOX\u00ae in Korean Adults With Chronic Migraine", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Migraine Disorders", 
        "condition_browse": {
            "mesh_term": "Migraine Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ethnically Korean with a diagnosis of chronic migraine\n\n        Exclusion Criteria:\n\n          -  Anticipated need for botulinum toxin treatment for any reason other than chronic\n             migraine during the study\n\n          -  Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral\n             sclerosis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02147561", 
            "org_study_id": "191622-148"
        }, 
        "intervention": {
            "arm_group_label": "botulinum toxin Type A", 
            "description": "Botulinum toxin Type A injected across specific head and neck muscles on Day 0.", 
            "intervention_name": "botulinum toxin Type A", 
            "intervention_type": "Biological", 
            "other_name": [
                "BOTOX\u00ae", 
                "onabotulinumtoxinA"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 22, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of Patients with Adverse Events", 
            "safety_issue": "No", 
            "time_frame": "28 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 05, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02147561"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Headache Impact Test-6 (HIT-6) Total Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 28"
            }, 
            {
                "measure": "Physician Global Assessment of Outcome on a 3-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "Day 28"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}